Belarus Pharmaceuticals and Healthcare Report Q2 2009
Business Monitor International, March 2009, Pages: 56
BMI's Belarus Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on Belarus' pharmaceuticals and healthcare industry.
Q209 sees Belarus added to BMI’s Pharmaceuticals & Healthcare quarterly reports for the first time, bringing the total coverage universe up to 71 markets. Of these countries, Belarus occupies 59th position in our Business Environment Rankings, highlighting its status as a true emerging pharmaceutical market. On a regional scale, Belarus places 18th in Central and Eastern Europe (CEE), ahead only of Commonwealth of Independent States (CIS) counterparts Moldova and Uzbekistan.
Belarus’ pharmaceutical market has undergone a period of robust growth in recent years, a trend we believe will prevail. Over the next five years, sales of pharmaceuticals, which include prescription drugs and over-the-counter medicines, will increase from US$0.62bn to US$1.28bn, representing a compound annual growth rate (CAGR) of 15.5%, among the highest in CEE. Nevertheless, growth from a low per capita spending base means that access to innovative therapies will remain limited. This trend is reinforced by nationalistic government policies which promote the local state owned industry and limited or no reimbursement for products not covered by the essential drugs list. Despite this recent data from the Association of International Pharmaceutical Manufacturers in Russia (AIPM) and Group of Companies Remedium shows a slight decline in the market share of leading domestic producers. Belarus' domestic pharmaceutical output showed continued progression in 2008.
According to the National Statistical Committee, production output rose 12.1% year-on-year (y-o-y) to 402.5bn (US$146mn). While this is by no means a blistering pace, BMI views growth as positive for the industry, as many plants only received Good Manufacturing Practice (GMP) certification during 2008.
Nevertheless it appears that widespread demand for more sophisticated, if not patented drugs, is resulting in local firms losing ground.
The regulatory environment has progressed significantly over five years. Widespread bioequivalence testing is now presence for all government tendered pharmaceuticals. Nevertheless, enforcement of intellectual property remains a challenge and despite claims that counterfeits are not an issue, it is unlikely that Belarus is free of fake products.
Despite a somewhat outdated model for healthcare, the ministry of health is making efforts to improve the situation. The 2009 budget approved a 34.7% increase in public healthcare expenditure. This, combined with ongoing improvement projects should help lower the country’s hefty disease burden. BMI’s Burden of Disease Database (BoDD) predicts that DALYs lost to non-communicable diseases should fall every year between 2009 and 2030. Nevertheless a high rate of infectious disease shows not only poor access to basic healthcare in rural areas. In a sign of developing standards in urban areas, 2009 should see the country’s first heart transplantation.
Executive Summary
Belarus Pharmaceuticals And Healthcare Industry SWOT
Belarus Political SWOT
Belarus Economic SWOT
Belarus Business Environment SWOT
Pharmaceutical Business Environment Ratings
Table: Central And Eastern Europe Pharmaceuticals Business Environment Ratings
Limits To Potential Returns
Risks To Realisation Of Returns
Belarus Market Summary
Regulatory Regime
Counterfeit Drugs
Intellectual Property Rights
Pricing And Reimbursement
Industry Developments
Epidemiology
Table: Disease Burden In Central And Eastern Europe, DALY’s Lost Per 100,000 Population
Healthcare Sector
Industry Forecast Scenario
Overall Market Forecast
Table: Belarus’ Drug Market Expenditure, 2004-2013
Key Growth Factors – Industry
Table: Belarus’ Health Expenditure, 2004-2013
Key Growth Factors – Macroeconomic
Table: Belarus – Economic Activity
Prescription Drug Market Forecast
Table: Belarus’ Prescription Drug Market, 2004-2013 (BYR mn unless otherwise stated)
Table: Top 10 ATC Level 2 Codes In Belarus By Pharmacy Sales, 2006-2007
Table: Top 10 ATC Level 2 Codes In Belarus By Hospital Sales, 2006-2007
Patented Drug Market Forecast
Table: Belarus’ Patented Drug Market, 2004-2013
Generic Drug Market Forecast
Table: Belarus’ Generic Drug Market, 2004-2013
OTC Drug Market Forecast
Table: Belarus’ OTC Market, 2004-2013 (BYR mn unless otherwise stated)
Pharmaceutical Export/Import Forecast
Table: Belarus’ Pharmaceutical Trade Balance, 2004-2013 (US$mn)
Other Healthcare Data Forecasts
Table: Belarus’ Other Health Indicators, 2004-2013
Key Risks To BMI’s Forecasts
Competitive Landscape
Table: The Top 10 Drugmakers In Belarus In H108 According To Pharmacy Sales
Table: The Top 10 Drugmakers In Belarus In H108 According To Hospital Sales
Table: The Top 10 Trade Names In Belarus According To Pharmacy Sales, 2007
Domestic Drugmakers
Foreign Drugmakers
Pharmaceutical Wholesale And Retail
Research And Development
Company Profiles.
Belbiopharm
Lekpharm
Country Snapshot: Belarus Demographic Data
Section 1: Population
Table: Demographic Indicators, 2005-2030
Table: Rural/Urban Breakdown, 2005-2030
Section 2: Education And Healthcare
Table: Education, 2000-2005
Table: Vital Statistics, 2005-2030
Section 3: Labour Market And Spending Power
Table: Employment Indicators, 2001-2006
Table: Consumer Expenditure, 2000-2012 (US$)
Table: Average Annual Wages, 2005-2009
BMI Forecast Modelling
How We Generate Our Pharmaceutical Industry Forecasts
Pharmaceutical Business Environment Ratings Methodology
Ratings Overview
Table: Pharmaceutical Business Environment Indicators
Weighting
Table: Weighting Of Components
Sources
- Belbiopharm
- Lekpharm
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW4
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
